Search

Allogene Therapeutics Inc

Fermé

SecteurSoins de santé

1.72 2.99

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.69

Max

1.75

Chiffres clés

By Trading Economics

Revenu

-70K

-43M

Ventes

4.6M

4.6M

BPA

-0.13

Marge bénéficiaire

-919.763

Employés

150

EBITDA

-251K

-40M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+492.49% upside

Dividendes

By Acuity

Prochains Résultats

5 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-110M

615M

Ouverture précédente

-1.27

Clôture précédente

1.72

Sentiment de l'Actualité

By Acuity

21%

79%

29 / 339 Classement par Healthcare

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 sept. 2026, 20:07 UTC

Allogene Therapeutics Inc is advancing, showing notable gains from Wednesday's close, despite remaining below its 20-day moving average.

16 sept. 2026, 23:01 UTC

Allogene Therapeutics Inc is moving higher in after-market hours, reflecting broader market trends following a 1.2% increase in U.S. retail sales for August.

10 sept. 2026, 20:07 UTC

Macro Event

Allogene Therapeutics Inc. shares are higher Thursday, following a cumulative gain since Wednesday's close, despite remaining below its 20-day moving average.

9 sept. 2026, 23:01 UTC

Allogene Therapeutics Inc shares are higher in after-market trading, reversing a three-session decline, though still below the 20-day moving average.

8 sept. 2026, 20:07 UTC

Allogene Therapeutics Inc shares are lower today amid broader market weakness, continuing a decline since Friday's close. No specific company news was identified.

3 sept. 2026, 19:36 UTC

Allogene Therapeutics Inc. shares are trading roughly flat with no specific news identified. The stock remains near the midpoint of its one-month trading range.

31 août 2026, 19:16 UTC

News

Allogene Therapeutics Inc shares are lower amid broader market declines following hawkish Fed comments. The company noted progress with cema-cel and FDA designations.

28 août 2026, 23:36 UTC

Allogene Therapeutics Inc shares are higher in after-market trading. No specific news was identified to explain this movement.

27 août 2026, 23:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the decline, though the stock has gained over the past month.

26 août 2026, 19:56 UTC

Allogene Therapeutics Inc shares are lower during Wednesday's session, continuing a decline since Tuesday amid broader market concerns over persistent inflationary pressures.

25 août 2026, 23:56 UTC

Allogene Therapeutics Inc. is trading roughly flat in after-market hours, maintaining a position near the upper end of its one-month range.

24 août 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though this marks the fifth consecutive day of lower closes for the asset.

21 août 2026, 19:56 UTC

Allogene Therapeutics Inc. shares are lower today, fluctuating within a routine range but remaining above their 20-day moving average.

20 août 2026, 22:16 UTC

Allogene Therapeutics Inc. shares are higher in after-market hours, despite earlier declines, amid rising U.S. Treasury yields and broader market pressure.

19 août 2026, 23:01 UTC

Allogene Therapeutics Inc. shares are lower in after-market hours, continuing a decline that began at the start of the session.

18 août 2026, 19:51 UTC

Correlated Moves

Allogene Therapeutics Inc. shares are trading lower amid broader market declines and rising Treasury yields, reflecting ongoing pressure in the biotechnology sector.

17 août 2026, 19:16 UTC

Correlated Moves
News

Allogene Therapeutics Inc shares rise following Citizens' Market Outperform rating and $6 price target. The broader Biotechnology sector also shows significant gains.

14 août 2026, 23:16 UTC

Allogene Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement. The stock remains above its 20-day moving average.

13 août 2026, 19:26 UTC

News

Allogene Therapeutics reported a net loss of $42.7 million, better than expectations, as shares trade lower amid concerns over a potential $500 million offering.

12 août 2026, 23:21 UTC

News

Allogene Therapeutics reports narrower net loss of $42.7 million, revenue of $4.64 million. Shares higher after positive trial results and $500 million securities offering announcement.

11 août 2026, 23:26 UTC

Allogene Therapeutics shares advanced during after-market hours, trading within a narrow range and remaining well above the 20-day moving average.

10 août 2026, 19:16 UTC

Allogene Therapeutics is trading higher, maintaining upward momentum despite a decline in U.S. stock futures following a labor market report.

7 août 2026, 19:16 UTC

Correlated Moves

Biotechnology stocks are rising, boosting Allogene Therapeutics shares. The ARK Genomic Revolution ETF has also increased, reflecting positive sector momentum.

6 août 2026, 19:46 UTC

Correlated Moves

Allogene Therapeutics shares are lower, reflecting broader market trends, as the Russell 2000 Index also declined during Thursday's session.

5 août 2026, 22:01 UTC

Allogene Therapeutics Inc shares are lower in after-market trading, reflecting a pullback from earlier gains amid broader market volatility following weaker U.S. job growth data.

3 août 2026, 20:06 UTC

Allogene Therapeutics Inc. shares are trading lower, continuing a decline since Friday's close, despite broader market gains in the S&P 500 and Nasdaq 100.

30 juil. 2026, 20:04 UTC

Correlated Moves
Event

Allogene Therapeutics receives RMAT and Fast Track designations from the FDA for cema-cel, contributing to gains in shares today.

29 juil. 2026, 23:51 UTC

Event
Correlated Moves

Allogene Therapeutics receives FDA RMAT and Fast Track designations for cema-cel, boosting shares higher in after-market hours. The Russell 2000 Index's rise may also contribute.

28 juil. 2026, 20:02 UTC

Allogene Therapeutics Inc shares are lower amid negative market sentiment following a significant sell-off in technology stocks across Asian markets.

27 juil. 2026, 18:07 UTC

Allogene Therapeutics Inc shares are higher today, despite earlier fluctuations. The market backdrop features a decline in oil prices, easing inflation concerns.

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

492.49% hausse

Prévisions sur 12 Mois

Moyen 10.25 USD  492.49%

Haut 14 USD

Bas 8 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

7 ratings

6

Achat

1

Maintien

0

Vente

Sentiment

By Acuity

29 / 339Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat